Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
AssigneeBayer Aktiengesellschaft
InventorThomas J. Kennedy
Life of this patent
Estimating the term…
Abstract
Disclosed herein are a methods of treating therapeutically, or metaphylactically infected animals susceptible to, or infected animal suffering from parasitic neurologic or abortigenic diseases such as Sarcocystidiae or Toxoplasmosis that are treatable with triazineone compound by administering thereto a pharmaceutically effective amount of ponazuril, including a single high dose therapeutic treatment.
Claims19
In an improved method of therapeutically treating a diseased animal suffering from a parasitic neurologic or abortigenic disease that is susceptible to being treated with a triazineone compound, comprising administering to the animal a pharmaceutically effective amount of the compound, the improvement comprising the triazineone compound which is ponazuril.
An improved method of metaphylactically treating animals infected with a parasite that is a causative agent for a neurologic or abortigenic disease that is susceptible to being treated with a triazineone compound, comprising administering thereto a metaphylactially-effective regimen of the triazineone compound, the improvement comprising the compound which is ponazuril.
A therapeutic composition comprising (a) ponazuril in a pharmaceutically effective amount to treat a diseased animal that is susceptible thereto (b) a carrier, and (c) optionally, an auxiliary agent.
A method of treating equine protozoal myeloencephalitis EPM comprising administering to an equine suspected of suffering therefore a therapeutically effective amount of ponazuril.
Dependencies are inferred from the claim text.